BDX - Becton Dickinson and Company - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0758871091

Medical Supplies, Laboratory Equipment, Diagnostic Products

Becton, Dickinson and Company is a global medical technology leader that develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products to healthcare institutions, physicians, researchers, clinical laboratories, the pharmaceutical industry, and the general public worldwide.

The company operates through three main segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical focuses on providing innovative solutions for medication delivery, vascular access, and infection prevention. This includes products such as IV catheters, syringes, and needles, as well as medication safety and infusion therapy systems. Additionally, they offer solutions for medication compounding, automated dispensing, and supply management.

The BD Life Sciences segment is dedicated to advancing the discovery and diagnosis of diseases. They offer a range of products, including specimen and blood collection systems, automated blood and tuberculosis culturing systems, molecular testing, and rapid diagnostic assays. They also provide solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

The BD Interventional segment focuses on providing solutions for surgical and interventional procedures. This includes products for hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and surgical infection prevention. They also offer peripheral intervention products, urology and critical care products, and other surgical solutions.

Founded in 1897, Becton, Dickinson and Company is headquartered in Franklin Lakes, New Jersey, and has a long history of innovation and commitment to improving healthcare outcomes. With a strong presence in over 190 countries, the company continues to drive innovation and advance healthcare worldwide.

For more information, please visit their website at https://www.bd.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for BDX - Becton Dickinson and Company  - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for BDX - Becton Dickinson and Company  - Stock & Dividends

BDX Stock Overview

Market Cap in USD 66,974m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 1987-01-01

BDX Stock Ratings

Growth 5y 1.14
Fundamental 15.4
Dividend 45.8
Rel. Performance vs Sector -0.74
Analysts 4.17/5
Fair Price Momentum 218.48 USD
Fair Price DCF 276.03 USD

BDX Dividends

Dividend Yield 12m 1.58%
Yield on Cost 5y 1.62%
Dividends CAGR 5y 4.02%
Payout Consistency 79.2%

BDX Growth Ratios

Growth 12m -14.03%
Growth Correlation 12m -54%
Growth Correlation 3m -18%
CAGR 5y 0.47%
CAGR/Mean DD 5y 0.05
Sharpe Ratio 12m -0.99
Alpha vs SP500 12m -27.03
Beta vs SP500 5y weekly 0.49
ValueRay RSI 87.85
Volatility GJR Garch 1y 21.33%
Price / SMA 50 2.16%
Price / SMA 200 -0.03%
Current Volume 1384.4k
Average Volume 20d 1326.9k

External Links for BDX Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of BDX stocks?
As of July 27, 2024, the stock is trading at USD 237.30 with a total of 1,384,408 shares traded.
Over the past week, the price has changed by +2.84%, over one month by +2.45%, over three months by +2.89% and over the past year by -13.50%.
What are the forecast for BDX stock price target?
According to ValueRays Forecast Model, BDX Becton Dickinson and Company will be worth about 237.5 in July 2025. The stock is currently trading at 237.30. This means that the stock has a potential upside of +0.07%.
Issuer Forecast Upside
Wallstreet Target Price 274.7 15.7
Analysts Target Price 301.2 26.9
ValueRay Target Price 237.5 0.07

The History and Market Status of Becton Dickinson and Company (BDX)

A Brief History

Becton, Dickinson and Company, commonly known as BD, began its journey in 1897. Founded by Maxwell Becton and Fairleigh S. Dickinson, its initial aim was to improve and simplify the process of delivering medications. Starting with glass syringes, BD has significantly grown, enhancing not only the medical field but also healthcare delivery globally. The company achieved many milestones over the years, like the development of the first-ever insulin syringe in 1924, and it has continued innovating in medical technology effectively till today.

Core and Side Businesses

BD's core mission revolves around advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. Its operations span across multiple segments:

  • Medical: Produces devices for medication delivery, diabetes care, and surgical instrument sterilization.
  • Life Sciences: Offers products for collecting and transporting diagnostics specimens, and instruments for cell analysis.
  • Interventional: Focuses on surgery, peripheral intervention, and urology and critical care treatments.

Alongside its primary operations, BD also collaborates with organizations worldwide to tackle global health issues, such as combating antimicrobial resistance and supporting health research and clinical diagnostics.

Current Market Status

As of 2023, BD (NYSE:BDX) continues to hold a significant position in the medical technology industry. Despite the challenges, such as regulatory pressures and global health crises, BD has shown resilience and adaptability. It continues to invest in research and development, aiming to bring forth innovations that can make a real difference in healthcare. The company's commitment to sustainability and addressing global health issues also adds to its reputation, potentially offering a competitive edge in the market. Financially, BD has maintained a steady performance, although the rapidly changing healthcare landscape calls for continuous innovation and strategic partnerships to sustain and enhance its market presence.